Breaking News
Wyeth is now a part of Pfizer Inc. The merger of local Wyeth and Pfizer entities may be pending in various jurisdictions and is subject to completion of various local legal and regulatory obligations. To learn more, please visit www.pfizer.com.

Health Care Professionals Log In

Sign Up for RELISTOR Updates

Gain access to additional content on the RELISTOR Web site and receive updates. You’ll also get at no charge, unlimited access to:

  • The 5–Minute Clinical Consult
  • Epocrates® Online Premium Reference
  • A.D.A.M. QuickSheets

Register Now
About Opioids and Constipation

RELISTOR is the first agent that targets the underlying cause of opioid-induced constipation (OIC) without impacting opioid-mediated analgesic effects on the central nervous system.1

RELISTOR Mechanism of Action Video

See how RELISTOR works to decrease the constipating effects of opioids without diminishing the central analgesic effects of opioids.1


This video requires the latest version of Adobe Flash Player.

get adobe flash player


RELISTOR decreases the constipating effects of opioids in patients with advanced illness
who are receiving palliative care1

  • RELISTOR is the first selective peripherally acting mu–opioid receptor antagonist displacing opioid binding in
    tissues such as the gastrointestinal tract1

RELISTOR does not diminish the central analgesic effects of opioids1

  • RELISTOR has a unique molecular structure that restricts it from crossing the blood-brain barrier1
  • In clinical studies, RELISTOR demonstrated:
    • No clinically relevant changes in pain scores from baseline1
    • No central opioid withdrawal3

Next: Efficacy »